Skip to Content
Global News Select

Roche 1st Half Net Profit Fell Despite Higher Sales; Backs 2021 Outlook — Update

   By Cecilia Butini 

Roche Holding AG said Thursday that profit for the first half of the year decreased though sales grew, driven by the diagnostics division.

The Swiss pharmaceutical major posted net profit for the period of 7.80 billion Swiss francs ($8.50 billion), compared with CHF8.08 billion a year earlier, on sales that rose to CHF30.71 billion from CHF29.28 billion.

Operating profit was CHF10.08 billion, down from CHF10.64 billion the previous year.

Sales in the diagnostics division grew 51% due to high demand for Covid-19 tests and strong momentum in routine testing, the company said. It added that its portfolio of Covid-19 tests contributed total sales of CHF2.5 billion, though the demand for such tests is likely to decrease in the second half.

The pharmaceutical division, on the other hand, saw a decline in sales of 3% in the first half, having taken a hit from the pandemic in the first quarter followed by some growth in the second, Roche said. The company added that the division experienced a CHF2.8 billion hit from biosimilars, particularly in the U.S., where biosimilars were launched for cancer drugs MabThera/Rituxan, Avastin and Herceptin.

In Europe, sales for new products more than compensated for the impact from biosimilars and were driven by Ronapreve, an antibody combination used to treat Covid-19, especially in Germany, Italy and France, Roche said.

Roche confirmed its outlook for the full year, saying that it expects sales growth in the low-to-mid-single-digits range at constant exchange rates, and core earnings per share growth broadly in line with sales. It added that it expects to further increase its dividend in Swiss francs.


Write to Cecilia Butini at


(END) Dow Jones Newswires

July 22, 2021 02:37 ET (06:37 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.